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To the Editor 
Since January 2020 when it was first  isolated in China, coronavirus disease 2019 
(COVID-19) has spread throughout the world and caused substantial morbidity and 
mortality.(1) Despite the rapidly growing knowledge base on the clinical course of the 
disease, no therapeutic agents have been proven to be effective for COVID-19. Further 
clarification of the clinical course of the disease could help in the development of effective 
treatment strategies. Wang and colleagues in their recent elegant study to investigate 
characteristics and prognostic factors in 339 elderly patients with COVID-19, observed a high 
proportion of severe and critical cases as well as high fatality rates.(2) Common 
complications included bacterial infection, acute respiratory distress syndrome as well as liver 
enzyme abnormalities. In their analyses to explore prognostic factors for fatal outcomes, 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were not found to be 
independently associated with the risk of mortality. Though it has been reported liver injury is 
more prevalent in severe cases of COVID-19,(3, 4) whether circulating levels of markers of 
liver injury could predict clinical outcomes in COVID-19 patients is uncertain. In this context, 
we aimed to determine the nature of the relationships of admission levels of five main 
markers of liver injury (ALT, AST, gamma-glutamyltransferase (GGT), alkaline phosphatase 
(ALP) and total bilirubin) with the risk of clinical outcomes in patients with COVID-19 using 
a systematic meta-analysis. 
We conducted this review using PRISMA and MOOSE guidelines (Supplementary 
Materials 1-2) and in accordance with a registered protocol in the PROSPERO International 
prospective register of systematic reviews (CRD42020183672). MEDLINE, Embase, and The 
Cochrane library were searched from 2019 to 17 May 2020 for published studies reporting on 
relationships between admission levels of markers of liver injury (GGT, ALT, AST, ALP and 
total bilirubin) and clinical outcomes in patients with COVID-19. The detailed search strategy 
has been reported in Supplementary Material 3. Outcomes were categorised into severe 
illness and mortality. Mean differences (95% CIs) for comparing mean levels of circulating 




associations between markers and outcomes were used as summary measures across 
studies.(5) The inverse variance-weighted method was used to effect estimates using random-
effects models to minimize the effect of heterogeneity. STATA release MP 16 (StataCorp LP, 
College Station, TX, USA) was used for all statistical analyses.  
Sixteen retrospective cohort studies comprising 10,540 COVID-19 patients were 
eligible (Table 1; Supplementary Materials 4-5). All studies were based in China. The 
average age at baseline ranged from approximately 38 to 71 years. Comparing elevated vs 
low levels of ALT and AST respectively, the RRs (95% CIs) of severe illness were 1.03 
(0.23-2.15) and 2.09 (0.44-9.9) respectively. Pooled analysis of 9 studies each showed 
significantly higher levels of ALT and AST in COVID-19 patients with severe illness 
compared to patients without severe illness: mean differences (95% CIs) of 9.15 U/L (1.47, 
16.82; p=0.02) and 12.60 U/L (8.43, 16.77; p<0.001) respectively (Fig. 1A)  
In pooled results of two studies each, the RRs (95% CIs) of mortality associated with 
elevated ALT and AST were 3.35 (2.37-4.75) and 10.42 (7.05-15.40) respectively. In results 
from single studies, increased levels of ALP and total bilirubin were each associated with an 
increased risk of mortality (Supplementary Material 6). Admission levels of AST and total 
bilirubin were higher in those who died; whereas ALT levels were not significantly different 
in both groups: mean differences (95% CIs) of 17.13 U/L (11.25, 23.01; p<0.001); 4.21 
µmol/l (3.97, 4.46; p<0.001) and 5.82 U/L (-2.57, 14.21; p=0.17) respectively. In single 
reports, levels of ALP and GGT were higher in those who died compared with survivors (Fig. 
1B).  
Taking the overall evidence together, the data supports a higher prevalence of 
elevated admission levels of markers of liver injury in severe or mortality due to COVID-19 
disease, which suggests that patients with elevated levels of liver markers at baseline (during 
admission) had higher risks of developing worse outcomes in COVID-19. The likely 
explanation for the worse outcomes observed in patients with baseline elevated markers of 
liver injury (as seen in chronic liver disease) could be attributed to compromised immune 




Irrespective of the fact that about 2-11% of patients with COVID-19 have liver 
comorbidities,(3) COVID-19 also causes liver injury. However, there is controversy regarding 
the causes of liver injury in COVID-19.(3, 4) Proposed explanations include (i) drug-induced 
liver injury; (ii) direct injury to the liver due to COVID-19 hepatitis(4); (iii) COVID-19 
induced myositis(4); (iv) binding of SARS CoV-2 directly to angiotensin-converting enzyme 
2 (ACE2) positive rich cholangiocytes and causing liver damage;(6) (v) hepatic congestion 
due to high levels of positive end expiratory pressure during mechanical ventilation;(4) and 
(vi) aggravation of liver injury by SARS CoV-2 in patients with pre-existing viral hepatitis.(7, 
8) In the absence robust association studies and formal risk prediction analyses, the overall 
evidence suggests that increased baseline levels of markers of liver injury could predict poor 
outcomes. The global prevalence of chronic liver disease remains high and continues to 
increase. Treatment options for COVID-19 are currently supportive; hence, there should be 
more intensive monitoring of levels of markers of liver injury during admission so that 
therapeutic approaches can be individually tailored.  
There are several limitations which deserve mention. First, the heterogeneous 
reporting of severe illness outcomes prompted the use of composite measures. Second, the 
possibility of patient overlap as all 16 studies were reported from China; there have been 
concerns with duplicate reporting of study participants in articles.(9) Third, due to the limited 
sample sizes and low events, some studies were unable to assess risk ratios to quantify the 
relationships. Finally, though we extracted data on baseline (admission) levels of these 
markers, studies were not very specific regarding the exact time of blood sampling in relation 
to the disease status; hence, these results may have some biases.  
In conclusion, elevated admission levels of markers of liver injury particularly the 
aminotransferases, may be associated with progression to severe disease or death in COVID-
19. Monitoring levels of these markers could assist in the optimum management of patients. 
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Fig. 1 Admission levels of markers of liver injury in (A) patients with or without severe 
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ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; 
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No Checklist item 
Reported on page 
No 
Title 




2 Provide a structured summary including, as applicable, background, objectives, data sources, study 
eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, 
conclusions and implications of key findings, systematic review registration number 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known Introduction 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 





5 Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if available, 
provide registration information including registration number 
Methods 
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years 
considered, language, publication status) used as criteria for eligibility, giving rationale 
Methods 
Information sources 7 Describe all information sources (such as databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched 
Methods 




Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if 




10 Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators 
Methods 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) and any 
assumptions and simplifications made 
Methods 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether 
this was done at the study or outcome level), and how this information is to be used in any data synthesis 
Methods 
Summary measures 13 State the principal summary measures (such as risk ratio, difference in means). Methods 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (such as I2 statistic) for each meta-analysis 
Methods 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, 
selective reporting within studies) 
Methods 
Additional analyses 16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified 
Methods 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 






18 For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up 
period) and provide the citations 
Results, Table 1 
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 12). Results  
Results of 
individual studies 
20 For all outcomes considered (benefits or harms), present for each study (a) simple summary data for each 
intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot 
 
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency Results, Figure 1; 
Supplementary 
material 6  
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see item 15) Not applicable 






24 Summarise the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (such as health care providers, users, and policy makers) 
Discussion 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as 
incomplete retrieval of identified research, reporting bias) 
Discussion 




Funding 27 Describe sources of funding for the systematic review and other support (such as supply of data) and role 






Supplementary Material 2. MOOSE checklist  
 




Criteria Brief description of how the criteria were handled in the review 
Reporting of background   
 Problem definition It is uncertain if circulating levels of markers of liver injury at admission 
could predict clinical outcomes in COVID-19 patients 
 Hypothesis statement In patients with COVID-19, do levels of admission liver injury biomarkers 
influence clinical outcomes? 
 Description of study outcomes Mortality, Severe disease, Respiratory failure, Acute respiratory distress 
syndrome, Poor clinical outcome 
 Type of exposure  Liver injury markers at admission 
 Type of study designs used Observational cohort designs and clinical studies 
 Study population Adult patients with COVID-19 
Reporting of search strategy should include  
 Qualifications of searchers Setor K. Kunutsor, PhD 
 Search strategy, including time period 
included in the synthesis and keywords 
Time period: from inception to 5 May 2020 
The detailed search strategy can be found in Supplementary Material 3 
 Databases and registries searched MEDLINE, Embase and The Cochrane Library 
 Search software used, name and version, 
including special features 
OvidSP was used to search Embase and MEDLINE 
EndNote X9 used to manage references  
 Use of hand searching We searched bibliographies of retrieved papers  
 List of citations located and those 
excluded, including justifications 
Details of the literature search process are outlined in the flow chart.  The 
citation list for excluded studies are available on request. 
 Method of addressing articles published 
in languages other than English 
Not applicable 
 Method of handling abstracts and 
unpublished studies 
Not applicable 
 Description of any contact with authors None 
Reporting of methods should include  
 Description of relevance or 
appropriateness of studies assembled for 
assessing the hypothesis to be tested 
Detailed inclusion and exclusion criteria are described in the Methods 
section. 
 Rationale for the selection and coding of 
data 
Data extracted from each of the studies were relevant to the population 
characteristics, study design, exposure, and outcome. 
 Assessment of confounding We assessed confounding by ranking individual studies on the basis of 
different adjustment levels and performed sub-group analyses to evaluate 
differences in the overall estimates according to levels of adjustment. 
 Assessment of study quality, including 
blinding of quality assessors; 
stratification or regression on possible 
predictors of study results 
Study quality was assessed based on the nine-star Newcastle–Ottawa Scale 
using pre-defined criteria namely: population representativeness, 
comparability (adjustment of confounders), ascertainment of outcome. 
Sensitivity analyses by several quality indicators such as study size, duration 
of follow-up, and adjustment factors. 
 Assessment of heterogeneity Results 
 Description of statistical methods in 
sufficient detail to be replicated 
Described in methods section 
 Provision of appropriate tables and 
graphics 
Table 1; Figure 1; Supplementary material 6 
Reporting of results should include  
 Graph summarizing individual study 
estimates and overall estimate 
Figure 1; Supplementary material 6 
 Table giving descriptive information for 
each study included 
Table 1 
 Results of sensitivity testing 
 
Not applicable  
 Indication of statistical uncertainty of 
findings 
95% confidence intervals were presented with all summary estimates 
Reporting of discussion should include  







 Justification for exclusion All studies were excluded based on the pre-defined inclusion criteria in 
methods section. 
 Assessment of quality of included studies Brief discussion included in ‘Methods’ section 
Reporting of conclusions should include  
 Consideration of alternative explanations 
for observed results 
Discussion 
 Generalization of the conclusions Discussed in the context of the results. 
 Guidelines for future research We recommend large-scale studies when more data becomes available 







Supplementary Material 3: MEDLINE literature search strategy 
 
1     exp gamma-Glutamyltransferase/ (11367) 
2     exp Alanine Transaminase/ (31182) 
3     exp Aspartate Aminotransferases/ (29579) 
4     exp Alkaline Phosphatase/ (54476) 
5     exp Bilirubin/ (24525) 
6     exp Liver/ (439637) 
7     exp Risk Factors/ (814890) 
8     1 or 2 or 3 or 4 or 5 or 6 or 7 (1342912) 
9     limit 8 to (english language and humans and yr="2019 -Current" and covid-19) (100) 






Supplementary Material 4: Selection of studies included in the meta-analysis 
104 Potentially relevant citations identified
From MEDLINE, Embase and reference list 
of relevant studies
82 excluded on the basis of title 
and/ or abstract
6 Articles excluded due to:
4 Exposure not relevant
1 Outcome not relevant
1 Duplicate
16 Articles included in review
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Table 1. Baseline characteristics of included studies of COVID-19 patients 
Author, year of  
publication 










Zhou, 2020 Jinyintan Hospital and Wuhan Pulmonary Hospital China Dec 2019 - Jan 2020 56.0 62.0 191 54 In-hospital mortality 5 
Huang, 2020 Jin Yintan Hospital China Dec 2019 - Jan 2020 49.0 73.0 41 13 ICU care 4 
Ruan, 2020 Jin Yin-tan Hospital and Tongji Hospital China  NR 57.7 68.0 150 68 Mortality 4 
Guan, 2020 National Health Commission China Dec 2019 - Jan 2020 47.0 58.1 1099 173 (67) Severe disease (Composite outcome 
of ICU admission, the use of 
mechanical ventilation, or death) 
4 
Liu, 2020 3 tertiary hospitals in Wuhan China Dec 2019 - Jan 2020 38.0 50.0 78 11 Severe disease 5 
Qian, 2020 5 hospitals in Zhejiang province China Jan - Feb 2020 50.0 40.7 91 9 Severe disease 4 
Zheng, 2020 North Hospital of Changsha first Hospital China Jan - Feb 2020 45.0 49.7 161 30 Severe disease 4 
Wang, 2020 Zhongnan Hospital of Wuhan University China Jan, 2020 56.0 54.3 138 36 ICU care 4 
Wang, 2020b Union Hospital in Wuhan China Jan - Feb 2020 42.0 46.0 69 14 SpO2<90% 4 
Wang, 2020c Renmin Hospital of Wuhan University China Jan – Feb 2020 71.0 49.0 339 65 Mortality 4 
Chen, 2020 Tongji Hospital in Wuhan China Jan - Feb 2020 62.0 62.0 274 113 Mortality 4 
Chen, 2020b National Health Commission China Dec 2019 - Jan 2020 NR NR 1,590 50 Mortality 6 
Cai, 2020 Third People’s Hospital of Shenzhen China Jan - Feb 2020 47.0 47.5 417 91 Severe disease 6 
Yang, 2020 Wuhan Jin Yin-tan hospital China Dec 2019 – Jan 2020 59.7 67.0 52 32 Mortality 4 
Lei, 2020 10 hospitals in Hubei Province China Dec 2019 – Mar 2020 56.0 47.2 5,771 1,186 Severe disease 5 
Xie, 2020 Jinyintan Hospital China Feb 2020 60.0 55.7 79 28 Severe disease 4 
ICU, intensive care unit; NOS, Newcastle-Ottawa Scale; NR, not reported 
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